Le Lézard
Classified in: Health
Subject: SVY

Hematology Rapid Tests & Point of Care Testing - In Vitro Diagnostics Market Analysis and Forecast Model


NEW YORK, May 22, 2018 /PRNewswire/ -- Hematology Rapid Tests & Point of Care Testing - In Vitro Diagnostics Market Analysis and Forecast Model

Read the full report: https://www.reportlinker.com/p05399505

Summary
Hematology Rapid Tests & Point of Care Testing - In Vitro Diagnostics Market Analysis and Forecast Model is built to better visualize quantitative market trends of Hematology Rapid Tests & Point of Care Testing within the In Vitro Diagnostics market.

The color-coded and fully-sourced models are equipped with epidemiology based indications with procedure volumes.To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share analysis.

Moreover, analyst comments with qualitative insight offer context for quantitative data.

Rapid Tests (RTs) are diagnostic assays designed for use at the point-of-care (POC), and can be adapted for use in low-resource settings.Point of Care Testing (POC) is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care.

POC is typically performed by non-laboratory personnel and the results are used for clinical decision making.

The Hematology Rapid Tests & Point of Care (POC) Market is segmented into Hemoglobin Rapid Tests & Point of Care (POC), Erythrocytes Rapid Tests & Point of Care (POC), Hematocrit Rapid Tests & Point of Care (POC), White Blood Cells (WBC) Rapid Tests & Point of Care (POC), Platelets Rapid Tests & Point of Care (POC), Other Hematology Rapid Tests & Point of Care (POC).

Each of the covered 39 country's market models are further segmented to provide granularity and pertinent data for respective market.

Key Inclusions of these market models are -
- Currently marketed Hematology Rapid Tests & POC and evolving competitive landscape.
- Insightful review of the key industry trends.
- Annualized total Hematology Rapid Tests & POC market revenue by segment and market outlooks from 2005-2024.
- Granular data on total procedures, units, average selling prices and market values by segment.

Robust methodologies and sources enable these market models to provide extensive and accurate overviews of markets. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders.

Built with help of thousands of interviews with demand side participants, majority of them are physicians, surgeons, and specialists within their therapeutic areas. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, Chile

Scope
This Market Model gives important, expert insight you won't find in any other source.

The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
- CMO executives who must have a deep understanding of the marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to buy
The model will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Hematology Rapid Tests & POC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hematology Rapid Tests & POC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific Hematology Rapid Tests & POC market from 2005-2024
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Read the full report: https://www.reportlinker.com/p05399505

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 20:25
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...

at 20:12
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...

at 19:29
Suffolk DBT is proud to announce the completion of their initial expansion to accommodate the growing need for DBT therapy...

at 18:24
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference. On April 26, 2024, the hearing will commence 11:15 a.m. Members of the public may observe the hearing by videoconference, by...

at 17:55
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....

at 17:43
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...



News published on and distributed by: